APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Glial Cell Line Derived Neurotrophic Factor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Glial Cell Line Derived Neurotrophic Factor Market Outlook and Growth Opportunities 2026

Report ID 173995290419 December 2025191 pages

Choose your research edition.

Industry ResearchGlial Cell Line Derived Neurotrophic Factor Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Glial Cell Line Derived Neurotrophic Factor Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal Glial Cell Line Derived Neurotrophic Factor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glial Cell Line Derived Neurotrophic Factor Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Glial Cell Line Derived Neurotrophic Factor Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Glial Cell Line Derived Neurotrophic Factor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Glial Cell Line Derived Neurotrophic Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Glial Cell Line Derived Neurotrophic Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Glial Cell Line Derived Neurotrophic Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Glial Cell Line Derived Neurotrophic Factor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Glial Cell Line Derived Neurotrophic Factor market include GlaxoSmithKline Plc, UniQure NV and Treeway BV, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Glial Cell Line Derived Neurotrophic Factor market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Glial Cell Line Derived Neurotrophic Factor and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Glial Cell Line Derived Neurotrophic Factor revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Glial Cell Line Derived Neurotrophic Factor market.

Glial Cell Line Derived Neurotrophic Factor Segment by Company

GlaxoSmithKline Plc

UniQure NV

Treeway BV

Glial Cell Line Derived Neurotrophic Factor Segment by Type

TW-002

LAUR-301

GSK-812

AMT-090

Others

Glial Cell Line Derived Neurotrophic Factor Segment by Application

Amyotrophic Lateral Sclerosis

Brain Ischemia

Parkinson's Disease

Retinal Degeneration

Others

Glial Cell Line Derived Neurotrophic Factor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Glial Cell Line Derived Neurotrophic Factor status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Glial Cell Line Derived Neurotrophic Factor key companies, revenue, market share, and recent developments.

3. To split the Glial Cell Line Derived Neurotrophic Factor breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Glial Cell Line Derived Neurotrophic Factor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Glial Cell Line Derived Neurotrophic Factor significant trends, drivers, influence factors in global and regions.

6. To analyze Glial Cell Line Derived Neurotrophic Factor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glial Cell Line Derived Neurotrophic Factor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glial Cell Line Derived Neurotrophic Factor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glial Cell Line Derived Neurotrophic Factor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Glial Cell Line Derived Neurotrophic Factor industry.

Chapter 3: Detailed analysis of Glial Cell Line Derived Neurotrophic Factor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Glial Cell Line Derived Neurotrophic Factor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Glial Cell Line Derived Neurotrophic Factor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Glial Cell Line Derived Neurotrophic Factor Industry Trends Table 2. Glial Cell Line Derived Neurotrophic Factor Industry Drivers Table 3. Glial Cell Line Derived Neurotrophic Factor Industry Opportunities and Challenges Table 4. Glial Cell Line Derived Neurotrophic Factor Industry Restraints Table 5. Global Glial Cell Line Derived Neurotrophic Factor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Glial Cell Line Derived Neurotrophic Factor Revenue Share by Company (2021-2026) Table 7. Global Glial Cell Line Derived Neurotrophic Factor Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Glial Cell Line Derived Neurotrophic Factor Key Company Manufacturing Base & Headquarters Table 9. Global Glial Cell Line Derived Neurotrophic Factor Company, Product Type & Application Table 10. Global Glial Cell Line Derived Neurotrophic Factor Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Glial Cell Line Derived Neurotrophic Factor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of TW-002 Table 15. Significant Companies of LAUR-301 Table 16. Significant Companies of GSK-812 Table 17. Significant Companies of AMT-090 Table 18. Significant Companies of Others Table 19. Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type (2021-2026) Table 23. Global Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Amyotrophic Lateral Sclerosis Table 25. Significant Companies of Brain Ischemia Table 26. Significant Companies of Parkinson's Disease Table 27. Significant Companies of Retinal Degeneration Table 28. Significant Companies of Others Table 29. Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application (2021-2026) Table 33. Global Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application (2027-2032) Table 34. Global Glial Cell Line Derived Neurotrophic Factor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Region (2021-2026) Table 37. Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Region (2027-2032) Table 39. Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Glial Cell Line Derived Neurotrophic Factor Sales Value Market Share by Country (2021-2026) Table 42. Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Glial Cell Line Derived Neurotrophic Factor Sales Value Market Share by Country (2027-2032) Table 44. GlaxoSmithKline Plc Company Information Table 45. GlaxoSmithKline Plc Business Overview Table 46. GlaxoSmithKline Plc Glial Cell Line Derived Neurotrophic Factor Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. GlaxoSmithKline Plc Glial Cell Line Derived Neurotrophic Factor Product Portfolio Table 48. GlaxoSmithKline Plc Recent Development Table 49. UniQure NV Company Information Table 50. UniQure NV Business Overview Table 51. UniQure NV Glial Cell Line Derived Neurotrophic Factor Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. UniQure NV Glial Cell Line Derived Neurotrophic Factor Product Portfolio Table 53. UniQure NV Recent Development Table 54. Treeway BV Company Information Table 55. Treeway BV Business Overview Table 56. Treeway BV Glial Cell Line Derived Neurotrophic Factor Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Treeway BV Glial Cell Line Derived Neurotrophic Factor Product Portfolio Table 58. Treeway BV Recent Development Table 59. Research Programs/Design for This Report Table 60. Authors List of This Report Table 61. Secondary Sources Table 62. Primary Sources List of Figures Figure 1. Glial Cell Line Derived Neurotrophic Factor Product Image Figure 2. Global Glial Cell Line Derived Neurotrophic Factor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glial Cell Line Derived Neurotrophic Factor Market Size (2021-2032) & (US$ Million) Figure 4. Global Glial Cell Line Derived Neurotrophic Factor Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. TW-002 Image Figure 8. LAUR-301 Image Figure 9. GSK-812 Image Figure 10. AMT-090 Image Figure 11. Others Image Figure 12. Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Glial Cell Line Derived Neurotrophic Factor Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type (2021-2032) Figure 15. Amyotrophic Lateral Sclerosis Image Figure 16. Brain Ischemia Image Figure 17. Parkinson's Disease Image Figure 18. Retinal Degeneration Image Figure 19. Others Image Figure 20. Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Glial Cell Line Derived Neurotrophic Factor Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application (2021-2032) Figure 23. Global Glial Cell Line Derived Neurotrophic Factor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Glial Cell Line Derived Neurotrophic Factor Sales Value (2021-2032) & (US$ Million) Figure 26. North America Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Glial Cell Line Derived Neurotrophic Factor Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Glial Cell Line Derived Neurotrophic Factor Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Glial Cell Line Derived Neurotrophic Factor Sales Value (2021-2032) & (US$ Million) Figure 32. South America Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Glial Cell Line Derived Neurotrophic Factor Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • TW-002
  • LAUR-301
  • GSK-812
  • AMT-090
  • Others
Applications
  • Amyotrophic Lateral Sclerosis
  • Brain Ischemia
  • Parkinson's Disease
  • Retinal Degeneration
  • Others
Companies covered
  • GlaxoSmithKline Plc
  • UniQure NV
  • Treeway BV

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Glial Cell Line Derived Neurotrophic Factor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Glial Cell Line Derived Neurotrophic Factor Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Glial Cell Line Derived Neurotrophic Factor Market Dynamics
  1. 2.1 Glial Cell Line Derived Neurotrophic Factor Industry Trends
  2. 2.2 Glial Cell Line Derived Neurotrophic Factor Industry Drivers
  3. 2.3 Glial Cell Line Derived Neurotrophic Factor Industry Opportunities and Challenges
  4. 2.4 Glial Cell Line Derived Neurotrophic Factor Industry Restraints
3 Glial Cell Line Derived Neurotrophic Factor Market by Company
  1. 3.1 Global Glial Cell Line Derived Neurotrophic Factor Company Revenue Ranking in 2025
  2. 3.2 Global Glial Cell Line Derived Neurotrophic Factor Revenue by Company (2021-2026)
  3. 3.3 Global Glial Cell Line Derived Neurotrophic Factor Company Ranking (2024-2026)
  4. 3.4 Global Glial Cell Line Derived Neurotrophic Factor Company Manufacturing Base and Headquarters
  5. 3.5 Global Glial Cell Line Derived Neurotrophic Factor Company Product Type and Application
  6. 3.6 Global Glial Cell Line Derived Neurotrophic Factor Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Glial Cell Line Derived Neurotrophic Factor Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Glial Cell Line Derived Neurotrophic Factor Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Glial Cell Line Derived Neurotrophic Factor Market by Type
  1. 4.1 Glial Cell Line Derived Neurotrophic Factor Type Introduction
  2. 4.1.1 TW-002
  3. 4.1.2 LAUR-301
  4. 4.1.3 GSK-812
  5. 4.1.4 AMT-090
  6. 4.1.5 Others
  7. 4.2 Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Type
  8. 4.2.1 Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Type (2021-2032)
  10. 4.2.3 Global Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type (2021-2032)
5 Glial Cell Line Derived Neurotrophic Factor Market by Application
  1. 5.1 Glial Cell Line Derived Neurotrophic Factor Application Introduction
  2. 5.1.1 Amyotrophic Lateral Sclerosis
  3. 5.1.2 Brain Ischemia
  4. 5.1.3 Parkinson's Disease
  5. 5.1.4 Retinal Degeneration
  6. 5.1.5 Others
  7. 5.2 Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Application
  8. 5.2.1 Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Application (2021-2032)
  10. 5.2.3 Global Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application (2021-2032)
6 Glial Cell Line Derived Neurotrophic Factor Regional Value Analysis
  1. 6.1 Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Region (2021-2032)
  3. 6.2.1 Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Region: 2021-2026
  4. 6.2.2 Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Glial Cell Line Derived Neurotrophic Factor Sales Value (2021-2032)
  7. 6.3.2 North America Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Glial Cell Line Derived Neurotrophic Factor Sales Value (2021-2032)
  10. 6.4.2 Europe Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Glial Cell Line Derived Neurotrophic Factor Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Glial Cell Line Derived Neurotrophic Factor Sales Value (2021-2032)
  16. 6.6.2 South America Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Glial Cell Line Derived Neurotrophic Factor Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Country, 2025 VS 2032
7 Glial Cell Line Derived Neurotrophic Factor Country-level Value Analysis
  1. 7.1 Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Country (2021-2032)
  3. 7.2.1 Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Country (2021-2026)
  4. 7.2.2 Global Glial Cell Line Derived Neurotrophic Factor Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Glial Cell Line Derived Neurotrophic Factor Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Glial Cell Line Derived Neurotrophic Factor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GlaxoSmithKline Plc
  2. 8.1.1 GlaxoSmithKline Plc Company Information
  3. 8.1.2 GlaxoSmithKline Plc Business Overview
  4. 8.1.3 GlaxoSmithKline Plc Glial Cell Line Derived Neurotrophic Factor Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GlaxoSmithKline Plc Glial Cell Line Derived Neurotrophic Factor Product Portfolio
  6. 8.1.5 GlaxoSmithKline Plc Recent Developments
  7. 8.2 UniQure NV
  8. 8.2.1 UniQure NV Company Information
  9. 8.2.2 UniQure NV Business Overview
  10. 8.2.3 UniQure NV Glial Cell Line Derived Neurotrophic Factor Revenue and Gross Margin (2021-2026)
  11. 8.2.4 UniQure NV Glial Cell Line Derived Neurotrophic Factor Product Portfolio
  12. 8.2.5 UniQure NV Recent Developments
  13. 8.3 Treeway BV
  14. 8.3.1 Treeway BV Company Information
  15. 8.3.2 Treeway BV Business Overview
  16. 8.3.3 Treeway BV Glial Cell Line Derived Neurotrophic Factor Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Treeway BV Glial Cell Line Derived Neurotrophic Factor Product Portfolio
  18. 8.3.5 Treeway BV Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst